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Epithelial cells function as mechanical barriers against invasion by pathogenic organisms and promote
intercellular communication through cell–cell junction complexes. Therefore, the permeability of the
gingival epithelial cell layer indicates a defensive capability against invasion by periodontal pathogens.
Accumulation of activated neutrophils is thought to be involved in the onset of inﬂammation. Here, we
review the effects of irsogladine maleate, a medication for gastric ulcers, on E-cadherin and chemokine
expression in gingival epithelial cells exposed to periodontopathogenic bacteria, in order to examine
the clinical efﬁcacy of irsogladine maleate in preventing periodontal inﬂammation.
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Periodontitis is an inﬂammatory condition caused by colonization
of the gingival sulcus by periodontopathogenic bacteria. In period-
ontitis, gingival epithelial cells actively contribute to inﬂammatory
processes, since they represent the ﬁrst line of defense against
microbial attacks. Epithelial cells function as mechanical barriers
against invasion by pathogenic organisms and promote intercellular
communication through cell–cell junction complexes [1–3]. In addi-
tion, they produce inﬂammatory cytokines and anti-microbial
peptides. Aggregatibacter actinomycetemcomitans is a major period-
ontopathogenic bacterium. Therefore, the interaction between epithe-
lial cells and A. actinomycetemcomitans has been suggested to play an
important role in the development of periodontitis.logy. Published by Elsevier B.V.
: þ81 82 257 5664.
.
 
OpE-cadherin, a key protein involved in the formation of desmo-
somes and adherens junctions, regulates the permeability of
epithelial cells [4,5]. The gingival junctional epithelium is located
at the base of the gingival sulcus, a strategically important interface.
E-cadherin in the gingival junctional epithelium is known to play an
important role against bacterial invasion [6], although a reduction
in levels of E-cadherin was observed in inﬂamed gingival tissue [6,7].
In addition, Porphyromonas gingivalis or A. actinomycetemcomitans
decreased E-cadherin expression in cultured gingival epithelial cells
[2,3]. In the gastric mucosal epithelium, disruption of E-cadherin
expression seems to increase epithelial permeability [8]. Thus, the
breakdown of E-cadherin has been suggested to lead to the disrup-
tion of the epithelial cell barrier function. Recovery of barrier function
may prevent bacterial invasion.
Chemotaxis of neutrophils to the site of infection is an important
step in the immune response induced by chemoattractants, such as
CXC chemokines CXCL-1 and CXCL-8 (interleukin [IL]-8). However,
an accumulation of activated neutrophils in lesion areas is observeden access under CC BY-NC-ND license.
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inﬂammation. The persistence of a local chronic host response may
alter the protective roles of inﬂammatory cells and have deleterious
effects on tissues [9–11]. In fact, the hyperactivity of neutrophils is
associated with periodontal tissue destruction [12,13]. Further, it
has also been reported that chronic inﬂammatory conditions often
result from the aberrant production of chemokines such as IL-8
[14]. Aberrant IL-8 production can lead to chronic inﬂammatory
conditions, as suggested for inﬂammatory diseases, such as rheu-
matoid arthritis [15,16]. Previous reports have shown that IL-8
is present in diseased human periodontal tissues [17–20], and the
levels of IL-8 in both periodontal tissue and gingival crevicular ﬂuid
are correlated to disease severity [21]. In addition, the expression
of IL-8 in diseased tissue, especially in the gingival epithelium,
is correlated to the migration of polymorphonuclear leukocyte
(PMNs) [22,23]. Therefore, blocking of excessive neutrophil activity
and regulation of CXC-chemokine production may represent poten-
tial therapeutic strategies for inﬂammation.
Irsogladine maleate has been used clinically as an anti-gastric
ulcer agent [24,25]. It has been shown to prevent gastric mucosal
damage without inhibiting gastric secretion in several animal
models [26–28]. Enhancement of gap junction intercellular com-
munication through the activation of a muscarinic acetylcholine
receptor and the increase in cyclic AMP levels in gastric epithelial
cells by irsogladine maleate are involved in mucosal protection
[29–32]. In addition, irsogladine maleate is also related to an
improvement in mucosal blood ﬂow that has been reduced because
of a disturbance of nitric oxide synthesis [33]. Irsogladine maleate
inhibits angiogenesis in vivo and in vitro [34–36]. Furthermore,
it decreases superoxide production in human neutrophils [37] andAggregatibacter
actinomycetemcomitan
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Fig. 1. Irsogladine maleate regulates gingival epithelial barrier function and neutro
periodontal disease.IL-8 production in human gingival epithelial cells (HGECs) [1,38,39],
suggesting that it has anti-inﬂammatory activity. Previous studies
have shown that irsogladine maleate enhances gap junction inter-
cellular communication through cyclic AMP in cultured gingival
epithelial cells as well as in pancreatic cancer cells [1,40]. Irsogla-
dine maleate may have multi-functions in gingival epithelial cells
that afford protection from periodontal inﬂammation. We review
the effect of irsogladine maleate on gingival epithelial cells, focusing
on E-cadherin expression and the accumulation of neutrophils.2. Effect of irsogladine maleate on E-cadherin expression in
A. actinomycetemcomitans-stimulated HGECs
Immunohistochemical studies have shown marked expression
of E-cadherin in the gingival junctional epithelium at cell–cell
junctions in uninfected control rats and A. actinomycetemcomi-
tans-infected rats pre-treated with irsogladine maleate. However,
components of the A. actinomycetemcomitans-infected gingival
junctional epithelium stained weakly for E-cadherin [41].
In vitro, the addition of A. actinomycetemcomitans to HGEC
cultures reduced the expression of E-cadherin at the mRNA and
protein levels. However, administration of irsogladine maleate, an
inhibitor of p38 mitogen-activated protein kinase (MAPK) and
extracellular signal-regulated kinase (ERK), help recover the
A. actinomycetemcomitans-induced reduction in E-cadherin
expression at the mRNA and protein levels, suggesting that p38
MAPK and ERK are involved in the reduction of E-cadherin
expression [41]. In addition, the exposure of A. actinomycetemco-
mitans to HGECs induced p38 MAPK and ERK phosphorylation,s
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se in the Gingival Epithelium
phil migration to the gingival epithelium, suggesting its utility for preventing
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pretreatment with irsogladine maleate prevented the tumor
necrosis factor (TNF)-a-induced reduction of transepithelial elec-
trical resistance in HGECs [42].3. Effect of irsogladine maleate on chemokine production
in A. actinomycetemcomitans-stimulated HGECs
In animal experiments, the inoculation of A. actinomycetemcomi-
tans at the gingival sulcus caused dilatation of intercellular spaces and
severe inﬁltration of the gingival epithelium by PMNs. Conversely,
irsogladine maleate-injected rats showedminimal migration of PMNs
through intercellular spaces [41]. An immunohistochemical study
showed positive reactions for cytokine-induced neutrophil chemoat-
tractant-2 (CINC-2a) in a small number of gingival epithelial cells
in control rats. A. actinomycetemcomitans-infected gingival epithelium
stained strongly for CINC-2a, although irsogladine maleate pretreat-
ment inhibited the A. Actinomycetemcomitans-induced increase in
positive reactions for CINC-2a in gingival epithelial cells [41].
A DNA microarray analysis using cultures of HGEC suggested that
the enhanced expression of CXCL-1, CXCL-2, CXCL-3, CXCL-6, and IL-8
was downregulated by irsogladine maleate in A. actinomycetemcomi-
tans-stimulated HGEC. In fact, exposure to A. actinomycetemcomitans
increased the levels of CXCL-1 and IL-8, and the addition of irsogla-
dine maleate or an ERK inhibitor to the culture abolished this increase
at the mRNA and protein levels. However, a p38 MAPK inhibitor had
little effect on the A. actinomycetemcomitans exposure-induced
increase in the mRNA expression of CXCL-1 and IL-8.
Compared to the unstimulated control, conditioned medium
obtained from A. actinomycetemcomitans-stimulated HGEC enhanced
human neutrophil chemotaxis in vitro. The co-incubation of either an
anti-CXCR-1 or anti-CXCR-2 antibody with HGEC inhibited this
chemotaxis. Furthermore, conditioned medium obtained from HGEC
co-treatedwith A. actinomycetemcomitans and irsogladinemaleate did
not induce chemotactic activity, suggesting that irsogladine maleate
reduces A. actinomycetemcomitans-induced neutrophil migration into
the gingival epithelium by suppressing CXC-chemokine expression
[41]. With regard to the inhibition of neutrophil migration, there is
still some debate about host protection against tissue destruction.
However, the persistence of a local chronic host response may alter
the protective roles of inﬂammatory cells and have deleterious effects
on tissues [9–11]. In fact, the use of anti-IL-8 neutralizing antibodies
has led to clinically relevant reductions in disease activity among
patients with palmoplantar pustulosis, a chronic inﬂammatory skin
disease characterized by overexpression of IL-8 [43].4. Conclusions
Although further studies are required, irsogladine maleate’s
ability to regulate the function of the physical barrier between
epithelial cells and neutrophil accumulation in the gingival
epithelium suggests that it may be useful for preventing period-
ontal inﬂammation (Fig. 1).Conﬂict of interest
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